BUSINESS● LOWJul 2 · Jul 2, 2026, 12:02 PM
AstraZeneca inks kidney therapy deal worth up to $1.77B with China’s CSPC
Seeking Alpha Tech
AstraZeneca has signed a kidney therapy deal valued at up to $1.77 billion with China's CSPC. This agreement represents a major collaboration in the pharmaceutical sector.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS28m agoTyson's beef and chicken headwinds may be dissipating -- J.P. MorganSeeking Alpha TechBUSINESS28m agoGraniteShares YieldBOOST TSLA ETF declares $0.1717 dividendSeeking Alpha Tech